Latest Insider Transactions at Ultragenyx Pharmaceutical Inc. (RARE)
This section provides a real-time view of insider transactions for Ultragenyx Pharmaceutical Inc. (RARE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Ultragenyx Pharmaceutical Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Ultragenyx Pharmaceutical Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 10
2024
|
Howard Horn Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,465
-7.48%
|
$388,180
$52.76 P/Share
|
|
Sep 16
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
700
+1.63%
|
-
|
|
Sep 03
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
91
-0.22%
|
$5,096
$56.19 P/Share
|
|
Sep 03
2024
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
20,000
-0.89%
|
$1,100,000
$55.85 P/Share
|
|
Aug 06
2024
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
20,000
-0.88%
|
$1,000,000
$50.17 P/Share
|
|
Jul 02
2024
|
Corazon (Corsee) D. Sanders |
SELL
Open market or private sale
|
Direct |
584
-4.64%
|
$23,360
$40.98 P/Share
|
|
Jun 18
2024
|
Daniel G Welch |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+16.55%
|
-
|
|
Jun 18
2024
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+20.92%
|
-
|
|
Jun 18
2024
|
Deborah Dunsire |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+17.57%
|
-
|
|
Jun 18
2024
|
Shehnaaz Suliman |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+20.92%
|
-
|
|
Jun 18
2024
|
Corazon (Corsee) D. Sanders |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+29.8%
|
-
|
|
Jun 18
2024
|
Amrit Ray |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+23.27%
|
-
|
|
Jun 18
2024
|
Michael Narachi |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+16.55%
|
-
|
|
Jun 12
2024
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,806
-14.47%
|
$441,270
$45.0 P/Share
|
|
Jun 10
2024
|
Corazon (Corsee) D. Sanders |
SELL
Open market or private sale
|
Direct |
1,737
-19.33%
|
$71,217
$41.1 P/Share
|
|
May 02
2024
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
354
-0.73%
|
$15,222
$43.66 P/Share
|
|
Apr 18
2024
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
142
-0.29%
|
$6,248
$44.1 P/Share
|
|
Apr 16
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14
-0.03%
|
$588
$42.31 P/Share
|
|
Mar 11
2024
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
11,509
-4.35%
|
$563,941
$49.93 P/Share
|
|
Mar 07
2024
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
12,195
-17.24%
|
$609,750
$50.87 P/Share
|
|
Mar 01
2024
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
1,011
-0.38%
|
$53,583
$53.76 P/Share
|
|
Mar 01
2024
|
Thomas Richard Kassberg CBO & EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-0.1%
|
$14,522
$53.69 P/Share
|
|
Mar 01
2024
|
Thomas Richard Kassberg CBO & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
18,757
+3.33%
|
-
|
|
Mar 01
2024
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,756
-5.28%
|
$199,068
$53.76 P/Share
|
|
Mar 01
2024
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,757
+10.83%
|
-
|
|
Mar 01
2024
|
Howard Horn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,400
+16.28%
|
-
|
|
Mar 01
2024
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
4,173
-4.47%
|
$221,169
$53.76 P/Share
|
|
Mar 01
2024
|
John Richard Pinion |
SELL
Payment of exercise price or tax liability
|
Direct |
60
-0.06%
|
$3,180
$53.69 P/Share
|
|
Mar 01
2024
|
John Richard Pinion |
BUY
Grant, award, or other acquisition
|
Direct |
18,757
+8.57%
|
-
|
|
Mar 01
2024
|
Dennis Karl Huang |
SELL
Payment of exercise price or tax liability
|
Direct |
470
-0.56%
|
$24,910
$53.69 P/Share
|
|
Mar 01
2024
|
Dennis Karl Huang |
BUY
Grant, award, or other acquisition
|
Direct |
18,757
+9.44%
|
-
|
|
Mar 01
2024
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,238
-2.47%
|
$65,614
$53.76 P/Share
|
|
Mar 01
2024
|
Eric Crombez EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,400
+27.99%
|
-
|
|
Mar 01
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
341
-0.82%
|
$18,073
$53.76 P/Share
|
|
Mar 01
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
121
-0.29%
|
$6,413
$53.69 P/Share
|
|
Mar 01
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,950
+25.0%
|
-
|
|
Mar 01
2024
|
Emil D Kakkis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
41,560
+3.39%
|
-
|
|
Mar 01
2024
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
17,417
-3.01%
|
$923,101
$53.69 P/Share
|
|
Mar 01
2024
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,768
-6.63%
|
$252,704
$53.76 P/Share
|
|
Mar 01
2024
|
Erik Harris EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,357
+11.43%
|
-
|
|
Feb 07
2024
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Direct |
30,000
-5.27%
|
$1,350,000
$45.0 P/Share
|
|
Jan 02
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+9.71%
|
$63,000
$21.0 P/Share
|
|
Dec 29
2023
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Direct |
30,000
-5.0%
|
$1,410,000
$47.87 P/Share
|
|
Dec 20
2023
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+3.9%
|
-
|
|
Oct 23
2023
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
39,878
-13.91%
|
$1,276,096
$32.78 P/Share
|
|
Oct 23
2023
|
Thomas Richard Kassberg CBO & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
39,878
+12.21%
|
$239,268
$6.86 P/Share
|
|
Oct 19
2023
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Direct |
47,853
-7.39%
|
$1,579,149
$33.52 P/Share
|
|
Oct 19
2023
|
Emil D Kakkis President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,853
+6.89%
|
$287,118
$6.86 P/Share
|
|
Oct 09
2023
|
Howard Horn Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,366
+50.01%
|
-
|
|
Sep 07
2023
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,163
-4.22%
|
$84,357
$39.67 P/Share
|